10/541991 JC12 Rec'd PCT/FTC 05 JUL 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

65369-US-PCT1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** Not Yet Assigned Filing Date INFORMATION DISCLOSURE Herewith - July 5, 2005 First Named Inventor Mohammad R. Marzabadi STATEMENT BY APPLICANT Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned (Use as many sheets as necessary)

Attorney Docket Number

Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
and		US- 6,727,264 .	04/27/2004	Marżabadi, et al.	· · · · · · · · · · · · · · · · · · ·
W		US- 6,441,000	08/27/2002	Gibson, et al.	
		<sup>US-</sup> 5,459,151	10/17/1995	Lombardo	
7-		US- 2004/0186103	09/23/2004	Marzabadi, et al.	
		US- 2004/0073036	04/15/2004	Marzabadi, et al.	
		US- 2004/0038855	02/26/2004	Salon, et al.	
V.		US- 2003/0077701	04/24/2003	Salon, et al.	•
mo		US- 10/719,358	Not Yet Published	Marzabadi, et al.	
0		US-			
		US-			
		US-			
• • • • •	- 7	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	•
		US-	<del></del>		
<del></del>	$\neg \uparrow$	US-	<u> </u>		
		US-			
	$\neg$	US-			
		US-	† · · · · · · · · · · · · · · · · · · ·		

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	١.
Initials*	No.'	Country Code <sup>3</sup> Number <sup>6</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	┸
Mil		′ WO 04/058727	07/15/2004	Bayer Pharmaceuticals		
79		, WO 04/005257	01/15/2004	Synaptic Pharmaceutical		Г
1		, WO 04/004714 ·	01/15/2004	Synaptic Pharmaceutical		Γ
V	<u> </u>	· WO 03/004027	01/16/2003	Synaptic Pharmaceutical	**************************************	П
mod		, WO 02/094799	11/28/2002	Neurogen	•	Г

Examiner	$\simeq$	1)100001	•	Date	11/11/20
Signature	arrina	NWW		Considered	1111412007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## 10/541991 JC12 Rec'd PCT/PTC 0 5 JUL 2005

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	Complete if Known			
	Application Number	Not Yet Assigned		
INFORMATION DISCLOSURE	Filing Date	Herewith - July 5, 2005		
STATEMENT BY APPLICANT	First Named Inventor	Mohammad R. Marzabadi		
OTATEMENT DI ATTEMPNIT	Art Unit	Not Yet Assigned   625		
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned 2001/		
Sheet 2 of 3	Attorney Docket Number	65369-US-PCT1		

Examiner	Cite		U. S. PATENT D Publication Date	Name of Patentee or	. Pages, Columns, Lines, Where
	No.1 MM-DD-YYYY Number-Kind Code <sup>2</sup> (f known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		U\$-			•
		US-			
		US-			
		US-			
		US			
		US-			
		US-			
	•	US-			
		US-			
		US-			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		US-			
		US-		• ,	
		US-			
		US-			
		US-	-		· ·
		US-	•		
		US-			· · · · · · · · · · · · · · · · · · ·
		us-			· · · · · · · · · · · · · · · · · · ·

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.¹	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Ľ
mol		, WO 02/030927	04/18/2002	Pierre Fabre Medicament	· ·	Γ
mo		WO 02/006245	01/24/2002	Synaptic Pharmaceutical		Г
and	••••••	₹ WO 02/002744	01/10/2002	Synaptic Pharmaceutical	•	Г
and	**********	✓ WO 00/021934	04/20/2000	Astra Zeneca	***************************************	
				•		

Examiner Signature	Linne N David	Date Considered	1/11/2067	•

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## 10/541991 JC12 Rec'd PCT/PTC 05 JUL 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/	PTO		Complete If Known		
Judania ia iani 1440.			Application Number	Not Yet Assigned	
INFORMATI	ON DIS	CLOSURE	Filing Date	Herewith - July 5, 2005	
STATEMEN	STATEMENT BY APPLICANT		First Named Inventor	Mohammad R. Marzabadi	
	(Use as many sheets as necessary)			Not Yet Assigned 1625	
(USE as man	y sneets as n	iocessary)	Examiner Name	Not Yet Assigned ZLAWS	
Sheet 3	of	3	Attorney Docket Number	65369-US-PCT1	

Examiner Initials*						
My	TAKEKAWA, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist", European Journal of Pharmacology, March 2002, 438, pp. 129-13					

Examiner	2. 100.	Date	11 12 10
Signature	Laire Deauly	Considered	1/1/1/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is o place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

MAR 0 3 2006

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/541,991		
Filing Date	July 5, 2005		
First Named Inventor	Mohammad R. Marzabadi		
Art Unit	Not Yet Assigned 1625		
Examiner Name	Not Yet Assigned ZNDAVIS		
Attorney Docket Number	GERRO LIG DOTA		

			U. S. PATENT [	OCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
m		US- 6,720,324	04-13-2004	Marzabadi, et al.	
<del>- 0</del>		US-			
		US-			
		US-			,
		US-			
***************************************		US-			
		US-			
	1	US-			
	$\vdash$	US-			
· · · · · · · · · · · · · · · · · · ·		US			
		US-			
	<b> </b>	US-			
		US			
		US-			
4	ļ	US-			
	Ì	US-			
		US-	······		
	1	US-			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>©</sup>			
			***************************************	***************************************	***************************************				
	ļ		T	••••••••••••••••••••••••••••••••••••••	***************************************				

	Control Contro		
Examiner Signature	String Volume	Date Considered	11/14/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.